Related Experiment Videos
Tumor necrosis factor-a antisense transfer remarkably improves hepatic graft viability
Tomoharu Yoshizumi1, Yoshikazu Yonemitsu, Yasuhiro Ikeda
1Division of Pathophysiological and Experimental Pathology, Department of Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. yosizumi@surg2.med.kyushu-u.ac.jp
Summary
Targeting tumor necrosis factor-alpha (TNF-alpha) with antisense oligodeoxynucleotides (TNF-AS) significantly improved liver graft survival in a rodent transplantation model, offering a potential solution for graft nonfunction.
Area of Science:
- Hepatology
- Transplantation Immunology
- Molecular Medicine
Background:
- Cold ischemia/reperfusion injury is a major challenge in liver transplantation.
- Activated Kupffer cells release inflammatory cytokines, particularly tumor necrosis factor-alpha (TNF-alpha), contributing to graft injury.
- Specific inhibition of TNF-alpha presents a potential strategy to enhance hepatic graft viability.
Purpose of the Study:
- To evaluate the efficacy of delivering TNF-alpha antisense oligodeoxynucleotides (TNF-AS) to Kupffer cells (KC).
- To assess the impact of TNF-AS treatment on liver graft viability in a rodent liver transplantation model.
Main Methods:
- Rodent liver transplantation model utilized.
- TNF-alpha antisense oligodeoxynucleotides (TNF-AS) were delivered to Kupffer cells (KC).
- Graft preservation involved 6-hour cold storage in lactated Ringer's solution at 4°C.
Main Results:
- TNF-AS treatment resulted in over 71% survival of animals with 6-hour preserved grafts, compared to 80% mortality in control groups.
- A significant reduction in hepatocyte enzyme release and serum TNF-alpha levels was observed 4 hours post-reperfusion in the TNF-AS group (P<0.05).
- Expression of TNF-alpha on KC and ICAM-1 on sinusoidal endothelial cells was completely suppressed by TNF-AS treatment.
Conclusions:
- TNF-AS delivery effectively enhances hepatic graft viability.
- This therapeutic approach holds promise for resolving hepatic graft nonfunction in clinical liver transplantation settings.